Dual PSMA and FDG PET Imaging for Patients With Advanced Prostate Cancer
NCT ID: NCT06335914
Last Updated: 2024-07-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
30 participants
INTERVENTIONAL
2024-09-30
2029-09-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
PSMA PET Registry (18F-DCFPyL)
NCT03535831
Detection of Clinically Significant Prostate Cancer With 18F-DCFPyL PET/MR
NCT03149861
Monitoring Patient Prostate Health Post Therapy
NCT07115914
PSMA-PET Registry for Recurrent Prostate Cancer
NCT03718260
18F-PSMA PET and MRI in the Primary Staging of Prostate Cancer Patients
NCT05141760
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PSMA and FDG PET Imaging
Participants advanced prostate cancer will undergo PSMA and FDG PET prior to starting their standard of care treatment and during treatment.
Ga 68 PSMA-11 PET
Positron emission tomography (PET) imaging using Ga68 PSMA 11 radiotracer
18F-DCFPyL PET
Positron emission tomography (PET) imaging using 18F-DCFPyL radiotracer.
FDG PET
Positron emission tomography (PET) imaging using (18) F-fluorodeoxyglucose radiotracer.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ga 68 PSMA-11 PET
Positron emission tomography (PET) imaging using Ga68 PSMA 11 radiotracer
18F-DCFPyL PET
Positron emission tomography (PET) imaging using 18F-DCFPyL radiotracer.
FDG PET
Positron emission tomography (PET) imaging using (18) F-fluorodeoxyglucose radiotracer.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histologically or cytologically confirmed prostate cancer (adenocarcinoma)
* Poor risk patients with mCSPC at study enrollment
* De novo or recurrent high volume mCSPC as per conventional imaging (CT chest abdomen pelvis, or MRI, plus bone scan) prior to starting ADT and ARPI
* High or low volume mCSPC plus PSA ≥4.0 after 6-8 months of initiating ADT
* Willing to undergo study PET scans and remain under the care of medical oncology, radiation oncology or urology physician at Princess Margaret Cancer Center.
* No prior PSMA or FDG PET imaging within the last 60 days at each specified time point on study
* Patients enrolled in clinical trials are eligible if they satisfy all other criteria of eligibility
Exclusion Criteria
* Inability to undergo or successfully complete PSMA PET and FDG PET imaging exams
* Unable to provide written consent by patient and their legal representatives
* In the opinion of the treating physician:
* conditions which would significantly impair the patient's ability to comply with study procedures and follow up
* Significant uncontrolled comorbidity, which may negatively impact the safety or interpretability of study PET imaging
* another active malignancy
* patient on dialysis
* another radioisotope or investigational systemic agent within 5 half-lives prior to PET imaging
18 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Health Network, Toronto
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Di (Maria) Jiang
Role: PRINCIPAL_INVESTIGATOR
Princess Margaret Cancer Centre/University Health Network
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CAPCR: 23-5595
Identifier Type: OTHER
Identifier Source: secondary_id
dualPET-mPC
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.